Case series of PsA-related uveitis
| Lambert and Wright 19765 | Paiva et al 20009 | Queiro et al 20026 | Sampaio-Barros et al 20067 | Abbouda et al 20168 | Present study | |
| Patients with PsA, n | 112 | 16 | 71 | 63 | 25 | 406 |
| Patients with uveitis, n (%) | 8 (7.1) | NA* | 13 (18) | 5 (8) | NA* | 20 (4.9) |
| Duration of PsA, years, mean±SD | – | – | 13±7 | – | – | 9.9±8.2 |
| Sex (women/men), n (% of women) | 63/49 (56) | 5/11 (31) | 34/37 (48) | – | 18/7 (72) | 202/204 (49.8) |
| Age at PsA onset, mean±SD | – | – | 35±12 | – | – | 46.3±12.3 |
| Age at uveitis onset, mean±SD | – | – | – | – | 41.84±13.72 | 46.8±16.9 |
| HLAB-27 positive, n (%) | ||||||
| PsA patients | 17 (31)† | 6 (67)‡ | – | – | – | 38 (9.4) |
| Uveitis patients | 2 (40)§ | 6 (67)‡ | 8 (61) | 5 (100) | 4 (21)¶ | 9 (45) |
| PsA pattern in complete series, n (%) | ||||||
| Peripheral pattern | – | 8 (50) | 46 (65) | – | 8 (32)** | 236 (58.1) |
| Axial and mixed pattern | – | 8 (50) | 25 (35) | – | 10 (40)** | 170 (41.9) |
| PsA pattern in uveitis, n (%) | ||||||
| Peripheral pattern | – | 8 (50) | 3 (23) | – | – | 12 (60) |
| Axial and mixed pattern | – | 8 (50) | 10(77) | – | – | 8 (40) |
| Uveitis onset, n (%) | ||||||
| Acute | – | 13 (81) | 9 (69) | 5 (100) | – | 20 (100) |
| Insidious | – | 3 (19) | 4 (31) | 0 | – | 0 (0) |
| Uveitis pattern, n (%) | ||||||
| Unilateral, n (%) | – | 4 (25) | 8 (61) | – | 8 (32) | 16 (80) |
| Bilateral, n (%) | – | 6 (37.5) | 5 (39) | – | 17 (68) | 4 (20) |
| Alternating, n (%) | – | 6 (37.5) | – | – | – | 0 (0) |
| Uveitis location, n (%) | ||||||
| Anterior | 8 (100) | 9 (56) | 10 (77) | 5 (100) | 23 (92) | 16 (80) |
| Posterior | 0 (0) | 7 (44) | 1 (7,7) | 0 | 1 (4) | 4 (20) |
| Panuveitis | 0 (0) | 0 | 2 (15,3) | 0 | 1 (4) | 0 (0) |
| Uveitis treatment, n (%) | ||||||
| Topic therapy | – | – | – | – | – | 20 (100) |
| Systemic | – | – | – | – | – | 15 (75) |
| Oral NSAIDs | – | – | – | – | – | 18 (90) |
| Systemic corticosteroids | – | – | 4 (31) | – | – | 8 (40) |
| cDMARDs | – | – | 2 (15)†† | – | – | 15 (75) |
| bDMARDs | – | – | – | – | – | 8 (40) |
| Uveitis follow-up (yearrs), mean±SD | – | – | – | – | 19 (76)‡‡ | 8.3±6.7 |
| Uveitis recurrence, n (%) | – | – | – | – | – | 10 (50) |
*NA (only include patients with PsA and uveitis).
†HLA-B27 was performed in 54 patients with a diagnosis of PsA.
‡HLA-B27 was typed in nine patients with a diagnosis of PsA and uveitis.
§HLA-B27 was performed in two patients with a diagnosis of iritis.
¶The total number of PsA patients with uveitis who underwent HLA B-27 typing was 19.
**In seven cases (28%), the specific joint involvement of the disease was not reported.
††One patient use cyclosporin-A and another one, azathioprine.
‡‡Follow-up was expressed in months (%) when available.
bDMARDs, biological disease-modifying antirheumatic drugs; cDMARDs, conventional DMARDs; NA, not applicable; NSAIDs, non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis.